[go: up one dir, main page]

CA2358395C - Formulations a liberation prolongee de derives d'erythromycine - Google Patents

Formulations a liberation prolongee de derives d'erythromycine Download PDF

Info

Publication number
CA2358395C
CA2358395C CA002358395A CA2358395A CA2358395C CA 2358395 C CA2358395 C CA 2358395C CA 002358395 A CA002358395 A CA 002358395A CA 2358395 A CA2358395 A CA 2358395A CA 2358395 C CA2358395 C CA 2358395C
Authority
CA
Canada
Prior art keywords
extended release
pharmaceutical composition
release pharmaceutical
composition
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002358395A
Other languages
English (en)
Other versions
CA2358395A1 (fr
Inventor
Laman A. Al-Razzak
Sheri L. Crampton
Linda E. Gustavson
Ho-Wah Hui
Nelly Milman
Susan J. Semla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BGP Products Operations GmbH
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25682218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2358395(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/838,900 external-priority patent/US6010718A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to CA002465698A priority Critical patent/CA2465698A1/fr
Priority claimed from CA002325541A external-priority patent/CA2325541C/fr
Publication of CA2358395A1 publication Critical patent/CA2358395A1/fr
Application granted granted Critical
Publication of CA2358395C publication Critical patent/CA2358395C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composition pharmaceutique à libération prolongée comprenant un dérivé de l'érythromycine et un polymère acceptable sur le plan pharmaceutique. La composition présente un profil de goût amélioré comparativement à une composition à libération immédiate de dérivé de l'érythromycine.
CA002358395A 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine Expired - Lifetime CA2358395C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002465698A CA2465698A1 (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/838,900 1997-04-11
US08/838,900 US6010718A (en) 1997-04-11 1997-04-11 Extended release formulations of erythromycin derivatives
CA002325541A CA2325541C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002325541A Division CA2325541C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002465698A Division CA2465698A1 (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Publications (2)

Publication Number Publication Date
CA2358395A1 CA2358395A1 (fr) 1998-10-22
CA2358395C true CA2358395C (fr) 2004-07-27

Family

ID=25682218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002358395A Expired - Lifetime CA2358395C (fr) 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine

Country Status (1)

Country Link
CA (1) CA2358395C (fr)

Also Published As

Publication number Publication date
CA2358395A1 (fr) 1998-10-22

Similar Documents

Publication Publication Date Title
CA2285266C (fr) Formulations a liberation prolongee de derives d'erythromycine
US6872407B2 (en) Extended release formulations of erythromycin derivatives
PL197448B1 (pl) Preparat farmaceutyczny o zmodyfikowanym uwalnianiu zawierający amoksycylinę i klawulanian potasowy oraz zastosowanie amoksycyliny i klawulanianu potasowego
US20050064033A1 (en) Extended release formulations of erythromycin derivatives
CA2358395C (fr) Formulations a liberation prolongee de derives d'erythromycine
CA2325541C (fr) Formulations a liberation prolongee de derives d'erythromycine
AU2007201031B2 (en) Extended release formulations of erythromycin derivatives
AU773863B2 (en) Extended release formulations of erythromycin derivatives
AU2003270948B2 (en) Extended Release Formulations of Erythromycin Derivatives
CA2465698A1 (fr) Formulations a liberation prolongee de derives d'erythromycine
HK1027023B (en) Extended release formulations of clarithromycin
AU2006201001A1 (en) Extended release formulations of erythromycin derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180306

MKEX Expiry

Effective date: 20180306